Lead Product(s) : Monepantel
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurizon Files IND Application to Support HEALEY ALS Platform Trial
Details : NUZ-001 (S-Monepantel) works by targetin TDP-43 protein aggregation, bein investigated for patients with amyotrophic lateral sclerosis.
Product Name : NUZ-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2024
Lead Product(s) : Monepantel
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Monepantel
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurizon’s NUZ-001 Reduces ALS TDP-43 Aggregation in Preclinical Studies
Details : NUZ-001(monepantel) has an unique mechanism of action in preventing the aggregation of TAR DNA-binding protein 43 (TDP-43), a key pathological feature of Amyotrophic lateral sclerosis.
Product Name : NUZ-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 19, 2024
Lead Product(s) : Monepantel
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Monepantel
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurizon Therapeutics Receives Orphan Product Designation for NUZ-001 in Europe
Details : Neurizon received OMPD for its lead drug candidate, NUZ-001, which is being evaluated for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : NUZ-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 11, 2024
Lead Product(s) : Monepantel
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Monepantel
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS
Details : PPL-1 (monepantel) is a positive allosteric modulator of DEG-3/DES-2 type nicotinic acetylcholine receptors (nAChRs). It is being evaluated for motor neurone disease & amyotrophic lateral sclerosis.
Product Name : PPL-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2024
Lead Product(s) : Monepantel
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alterity to Present at the 7th International Congress of Multiple System Atrophy
Details : Alterity will be presenting further information on ATH434. The new results to be presented include data on blood pressure following change in body position, which demonstrate that ATH434 does not lower blood pressure when subjects move to the standing po...
Product Name : ATH434
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 26, 2021
Details : The scientific investigation of ATH434, along with the results from the Phase 2 study, will augment the development and optimization of novel compounds expected to emerge from the new patent.
Product Name : ATH434
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2021
Alterity Therapeutics Meeting with US FDA Provides Development Pathway for ATH434
Details : The pre-IND (Investigational New Drug) meeting was to obtain input on the clinical development plan for ATH434, including feedback on the Phase 2 study design.
Product Name : ATH434
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2020
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Details : The abstract, presentation and article share findings from Alterity's completed Phase 1 trial of leading drug candidate ATH434, which evaluated the safety, tolerability, and pharmacokinetics in healthy adult and older adult volunteers.
Product Name : ATH434
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 21, 2020
New Data Independently Confirms and Extends Laboratory Findings and Expands Safety Profile of ATH434
Details : The new data, from an experiment testing ATH434 in an animal model of Multiple System Atrophy (MSA), independently confirm and extend previous findings demonstrating that ATH434 reduces α-synuclein pathology, preserves neurons, and improves motor perfor...
Product Name : ATH434
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2020